Benefits of Early, Aggressive, and Appropriate Intervention in Rheumatoid Arthritis |
|
|---|---|
| Audience: | US-based primary care physicians, rheumatologists, primary care nurse practitioners, and physician assistants who care for patients with rheumatoid arthritis. |
| Description: | In this activity, experts in management of rheumatoid arthritis discuss the importance of early, aggressive management of rheumatoid arthritis. Upon completion of this activity, participants will be able to: Incorporate treatment with biological DMARDs early in the course of RA not only to control symptoms but also to prevent disease progression and minimize joint damage Apply appropriate sequencing of therapy in cases of inadequate response to initial treatment with DMARDs Assess tolerability and safety of biological DMARDs, especially risks of developing infections and malignancies Use objective measurements to evaluate patients with RA and provide timely referral to rheumatologists |
| Author: | Paul Emery, MA, MD |
| Provider: | Peer View Press |
| Author Bio: | Paul Emery, MA, MD Professor or Rheumatology University of Leeds Leeds, United Kingdom Paul Emery, MA, MD, has a financial interest/relationship or affiliation in the form of: Consultant for Abbott Laboratories; Bristol-Myers Squibb Company; Roche Laboratories Inc.; Schering-Plough Corporation; and Wyeth Pharmaceuticals Inc. |
| Sponsor: | University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. This activity is supported by an educational grant from Bristol Myers Squibb. |
| Categories: | Registration required, Free |
 Add to learning plan
 Return to Course Catalogue
|
|
